Correction: (A. Bateman, et al, Cancer Res. (2000), 60(17) (2492-2497))

Andrew Bateman, Francis Bullough, Stephen Murphy, Lisa Emiliusen, Dimitri Lavillette, François Loic Cosset, Roberto Cattaneo, Stephen J Russell, Richard Geoffrey Vile

Research output: Contribution to journalComment/debate

Abstract

It has come to our attention that the data shown in Figure 3 of our manuscript (A. Bateman et al., Cancer Res. 60: 1492-1497, 2000) are derived from a slightly different experimental protocol than those described in the following text from page 1496 (lines 28-35): Established Tumors Can Be Eradicated by Transduction with Plasmid DNA Encoding FMG cDNA. Human tumor xenografts of HT1080 or Mel624 cells were injected s.c. into nude athymic mice at a dose of 106 tumor cells/mouse. At this dose, 90-100% of mice develop small, palpable tumors by 72 h after tumor cell seeding. Tumors were transfected with 10 mg of plasmid DNA complexed with Efectene lipid (Qiagen). The subsequent development of tumor growth was then measured with time as shown in Fig. 3. The protocol should read as follows: Tumorigenicity Can Be Abrogated by Pretransduction with Plasmid DNA Encoding FMG cDNA. Tumor cells were transfected with 10 mg of plasmid DNA complexed with Efectene lipid (Qiagen). Twenty-four h later, transduced human tumor xenografts of HT1080 or Mel624 cells were injected s.c. into nude athymic mice at a dose of 106 tumor cells/mouse. At this dose, 90-100% of control mice develop small, palpable tumors by 72 h after tumor cell seeding. The subsequent development of tumor growth was then measured with time as shown in Fig. 3. All other data reported in the manuscript have been thoroughly checked and are correct as described.

Original languageEnglish (US)
Pages (from-to)4975-4978
Number of pages4
JournalCancer Research
Volume60
Issue number17
StatePublished - 2000

Fingerprint

Neoplasms
Nude Mice
Plasmids
Manuscripts
DNA
Growth and Development
Heterografts
Complementary DNA
Lipids

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bateman, A., Bullough, F., Murphy, S., Emiliusen, L., Lavillette, D., Cosset, F. L., ... Vile, R. G. (2000). Correction: (A. Bateman, et al, Cancer Res. (2000), 60(17) (2492-2497)). Cancer Research, 60(17), 4975-4978.

Correction : (A. Bateman, et al, Cancer Res. (2000), 60(17) (2492-2497)). / Bateman, Andrew; Bullough, Francis; Murphy, Stephen; Emiliusen, Lisa; Lavillette, Dimitri; Cosset, François Loic; Cattaneo, Roberto; Russell, Stephen J; Vile, Richard Geoffrey.

In: Cancer Research, Vol. 60, No. 17, 2000, p. 4975-4978.

Research output: Contribution to journalComment/debate

Bateman, A, Bullough, F, Murphy, S, Emiliusen, L, Lavillette, D, Cosset, FL, Cattaneo, R, Russell, SJ & Vile, RG 2000, 'Correction: (A. Bateman, et al, Cancer Res. (2000), 60(17) (2492-2497))', Cancer Research, vol. 60, no. 17, pp. 4975-4978.
Bateman A, Bullough F, Murphy S, Emiliusen L, Lavillette D, Cosset FL et al. Correction: (A. Bateman, et al, Cancer Res. (2000), 60(17) (2492-2497)). Cancer Research. 2000;60(17):4975-4978.
Bateman, Andrew ; Bullough, Francis ; Murphy, Stephen ; Emiliusen, Lisa ; Lavillette, Dimitri ; Cosset, François Loic ; Cattaneo, Roberto ; Russell, Stephen J ; Vile, Richard Geoffrey. / Correction : (A. Bateman, et al, Cancer Res. (2000), 60(17) (2492-2497)). In: Cancer Research. 2000 ; Vol. 60, No. 17. pp. 4975-4978.
@article{e37a11997e204a31adf1e58165e12efb,
title = "Correction: (A. Bateman, et al, Cancer Res. (2000), 60(17) (2492-2497))",
abstract = "It has come to our attention that the data shown in Figure 3 of our manuscript (A. Bateman et al., Cancer Res. 60: 1492-1497, 2000) are derived from a slightly different experimental protocol than those described in the following text from page 1496 (lines 28-35): Established Tumors Can Be Eradicated by Transduction with Plasmid DNA Encoding FMG cDNA. Human tumor xenografts of HT1080 or Mel624 cells were injected s.c. into nude athymic mice at a dose of 106 tumor cells/mouse. At this dose, 90-100{\%} of mice develop small, palpable tumors by 72 h after tumor cell seeding. Tumors were transfected with 10 mg of plasmid DNA complexed with Efectene lipid (Qiagen). The subsequent development of tumor growth was then measured with time as shown in Fig. 3. The protocol should read as follows: Tumorigenicity Can Be Abrogated by Pretransduction with Plasmid DNA Encoding FMG cDNA. Tumor cells were transfected with 10 mg of plasmid DNA complexed with Efectene lipid (Qiagen). Twenty-four h later, transduced human tumor xenografts of HT1080 or Mel624 cells were injected s.c. into nude athymic mice at a dose of 106 tumor cells/mouse. At this dose, 90-100{\%} of control mice develop small, palpable tumors by 72 h after tumor cell seeding. The subsequent development of tumor growth was then measured with time as shown in Fig. 3. All other data reported in the manuscript have been thoroughly checked and are correct as described.",
author = "Andrew Bateman and Francis Bullough and Stephen Murphy and Lisa Emiliusen and Dimitri Lavillette and Cosset, {Fran{\cc}ois Loic} and Roberto Cattaneo and Russell, {Stephen J} and Vile, {Richard Geoffrey}",
year = "2000",
language = "English (US)",
volume = "60",
pages = "4975--4978",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Correction

T2 - (A. Bateman, et al, Cancer Res. (2000), 60(17) (2492-2497))

AU - Bateman, Andrew

AU - Bullough, Francis

AU - Murphy, Stephen

AU - Emiliusen, Lisa

AU - Lavillette, Dimitri

AU - Cosset, François Loic

AU - Cattaneo, Roberto

AU - Russell, Stephen J

AU - Vile, Richard Geoffrey

PY - 2000

Y1 - 2000

N2 - It has come to our attention that the data shown in Figure 3 of our manuscript (A. Bateman et al., Cancer Res. 60: 1492-1497, 2000) are derived from a slightly different experimental protocol than those described in the following text from page 1496 (lines 28-35): Established Tumors Can Be Eradicated by Transduction with Plasmid DNA Encoding FMG cDNA. Human tumor xenografts of HT1080 or Mel624 cells were injected s.c. into nude athymic mice at a dose of 106 tumor cells/mouse. At this dose, 90-100% of mice develop small, palpable tumors by 72 h after tumor cell seeding. Tumors were transfected with 10 mg of plasmid DNA complexed with Efectene lipid (Qiagen). The subsequent development of tumor growth was then measured with time as shown in Fig. 3. The protocol should read as follows: Tumorigenicity Can Be Abrogated by Pretransduction with Plasmid DNA Encoding FMG cDNA. Tumor cells were transfected with 10 mg of plasmid DNA complexed with Efectene lipid (Qiagen). Twenty-four h later, transduced human tumor xenografts of HT1080 or Mel624 cells were injected s.c. into nude athymic mice at a dose of 106 tumor cells/mouse. At this dose, 90-100% of control mice develop small, palpable tumors by 72 h after tumor cell seeding. The subsequent development of tumor growth was then measured with time as shown in Fig. 3. All other data reported in the manuscript have been thoroughly checked and are correct as described.

AB - It has come to our attention that the data shown in Figure 3 of our manuscript (A. Bateman et al., Cancer Res. 60: 1492-1497, 2000) are derived from a slightly different experimental protocol than those described in the following text from page 1496 (lines 28-35): Established Tumors Can Be Eradicated by Transduction with Plasmid DNA Encoding FMG cDNA. Human tumor xenografts of HT1080 or Mel624 cells were injected s.c. into nude athymic mice at a dose of 106 tumor cells/mouse. At this dose, 90-100% of mice develop small, palpable tumors by 72 h after tumor cell seeding. Tumors were transfected with 10 mg of plasmid DNA complexed with Efectene lipid (Qiagen). The subsequent development of tumor growth was then measured with time as shown in Fig. 3. The protocol should read as follows: Tumorigenicity Can Be Abrogated by Pretransduction with Plasmid DNA Encoding FMG cDNA. Tumor cells were transfected with 10 mg of plasmid DNA complexed with Efectene lipid (Qiagen). Twenty-four h later, transduced human tumor xenografts of HT1080 or Mel624 cells were injected s.c. into nude athymic mice at a dose of 106 tumor cells/mouse. At this dose, 90-100% of control mice develop small, palpable tumors by 72 h after tumor cell seeding. The subsequent development of tumor growth was then measured with time as shown in Fig. 3. All other data reported in the manuscript have been thoroughly checked and are correct as described.

UR - http://www.scopus.com/inward/record.url?scp=85024260229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024260229&partnerID=8YFLogxK

M3 - Comment/debate

AN - SCOPUS:85024260229

VL - 60

SP - 4975

EP - 4978

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 17

ER -